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Objectives The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal
pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients
with stable coronary disease, the incremental prognostic information obtained from these two biomarkers com-
pared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-
converting enzyme (ACE) inhibition.
Background The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear.
Methods Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary ar-
tery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With
Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox re-
gression was used to assess the association between natriuretic peptide concentrations and the incidence of
cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.
Results The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure,
and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased
risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality,
heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive
accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for car-
diovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end
points was similar, regardless of either BNP or NT-proBNP baseline concentrations.
Conclusions In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong
and incremental prognostic information to traditional risk factors. (J Am Coll Cardiol 2007;50:205–14)
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B-type natriuretic pep-
tide (BNP) and N-
terminal (NT) pro-
BNP are peptide frag-
ments derived from a
common precursor
molecule, proBNP (1). Originally
introduced in clinical medicine as
diagnostic tools for heart failure
(2), BNP and NT-proBNP con-
centrations have been shown to be
strongly predictive of short- and
ong-term survival in patients with acute coronary syndromes
3–8). Although the association between BNPs and survival
as been well documented in a wide spectrum of cardiovascular
iseases, some important questions remain unresolved. First,
o BNP and NT-proBNP provide independent prognostic
nformation in coronary artery disease patients at low risk?
oth BNP and NT-proBNP have recently been identified as
trong prognostic indicators in patients with stable coronary
rtery disease (9–13), but a high rate of clinically suspected
eart failure (up to 60%) in those populations suggest that the
esults may not be generalizable to low-risk stable coronary
rtery disease patients without clinical heart failure and with
reserved systolic ventricular function. Second, can the associ-
tion between BNPs and cardiovascular mortality be
See page 215
xplained mainly by the ability to predict heart failure, or are
hese peptides also related to the incidence of coronary isch-
mic events or stroke? Although previous studies have docu-
ented strong associations with outcome, they have not had
ufficient statistical power to look at specific cardiovascular end
oints. Third, do BNPs provide clinically important incremen-
al prognostic information to traditional risk factors? Although
tudies in patients with coronary artery disease have demon-
trated that elevated levels of BNPs are statistically significant
redictors in multivariable models, that does not necessarily
mply better predictive performance (14). Finally, in patients
ith stable coronary disease and preserved left ventricular
ystolic function, can BNP and NT-proBNP be used to
dentify high-risk patients who may benefit from intervention
ith angiotensin-converting-enzyme (ACE) inhibitors? The
CE inhibitors have proved to be effective in reducing mor-
ality and morbidity in patients at high risk (15,16), but failed
o reduce cardiovascular death, myocardial infarction, and
oronary revascularization in low-risk patients with stable
oronary artery disease (17). Based on the strong prognostic
alue of BNPs, we hypothesized that measurement of these
ubstances would prove helpful in identifying patients who
enefit from ACE inhibition.
To address these questions, we measured plasma BNP
nd NT-proBNP concentrations in a subcohort of 3,761
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BNP  B-type natriuretic
peptide
EDTA  ethylenediamine-
tetraacetic acid
NT-proBNP  N-terminal
pro-B-type natriuretic
peptideatients with stable coronary disease and preserved systolic aunction included in the PEACE (Prevention of Events
ith Angiotensin-Converting Enzyme Inhibition) trial
nd related peptide concentrations at baseline to the inci-
ence of subsequent fatal and nonfatal cardiovascular events
nd cardiovascular mortality.
ethods
tudy subjects. The design, entry criteria, and main results
f the PEACE trial have been described previously (17). In
rief, from November 1996 to June 2000, 8,290 patients
ere randomized to the ACE inhibitor trandolapril or
lacebo and followed up for a median of 4.8 years. Entry
riteria included: age 50 years or more, documented coro-
ary artery disease, and left ventricular ejection fraction
40% by contrast or radionuclide ventriculography or
chocardiogram. Exclusion criteria included: serum creati-
ine 2.0 mg/dl, valvular heart disease requiring surgical
ntervention, or plans for coronary revascularization. All
atients who had baseline ethylenediaminetetraacetic acid
EDTA) plasma samples for measurement of BNP and
T-proBNP were included in this substudy.
lood sampling procedures and biochemical assays. Sam-
les of EDTA-anticoagulated venous blood were obtained
efore randomization. The test tube was centrifuged at
oom temperature, and plasma was aspirated and frozen at
20°C at individual centers. Within 3 months of collection,
lasma samples were shipped on dry ice to the central
aboratory for storage at 70°C or colder pending analysis.
or natriuretic peptide analyses, samples were shipped on
ry ice to the University of Oslo, where samples were
hawed and analyzed for BNP and NT-proBNP on the
ame day. Plasma samples were kept on ice throughout the
ay, avoiding refreezing and rethawing. The stability of
amples during long-term storage was assessed by plotting
he duration of storage versus peptide concentration, and no
ndication of degradation during long-term storage of either
NP or NT-proBNP was observed (data not shown).
The BNP concentrations in plasma were determined
sing a 2-step microparticle enzyme immunoassay on an
bbott Ax Sym analyzer (Abbott Laboratories, Abbott
ark, Illinois). The interassay coefficient of variation was
2.7% at a concentration of 32 pg/ml (n  142), 8.7% at a
oncentration of 146 pg/ml (n  128), and 8.6% at a
oncentration of 480 pg/ml (n  87). The measuring range
or the assay was 15 to 4,000 pg/ml. The Food and Drug
dministration (FDA)-approved BNP decision threshold
or heart failure is 100 pg/ml.
The NT-proBNP concentrations in plasma were deter-
ined with an electrochemiluminescence immunoassay on a
odular platform (Roche Diagnostics, Basel, Switzerland).
he interassay coefficient of variation was 4.5% at a con-
entration of 21 pg/ml (n  100) and 2.2% at a concentra-
ion of 9,120 pg/ml (n 100). The measuring range for the
ssay was 5 to 34,000 pg/ml. The FDA-approved NT-
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July 17, 2007:205–14 BNP, NT-proBNP, and Prognosis in Stable CADroBNP decision threshold for heart failure is 125 pg/ml for
hose age75 years and 450 pg/ml for those age75 years.
For the measurement of C-reactive protein, aliquots were
hipped frozen on dry ice to the TIMI (Thrombolysis in
yocardial Infarction) Biomarker Laboratory (Boston,
assachusetts), where they were thawed and analyzed in
atch. High-sensitivity testing for C-reactive protein was
erformed using the CRP-Latex (II) immunoturbidimetric
ssay (Denka Seiken, Tokyo, Japan) on a Hitachi 911
mmunoanalyzer (Roche Diagnostics, Indianapolis, Indi-
na). This assay has a minimal detectable concentration of
.03 mg/l and a total imprecision of 5.1% and 2.5% at
oncentrations of 0.2 and 1.9 mg/l, respectively (18). Cre-
tinine and total cholesterol concentrations in serum were
etermined by routine laboratory methods. Glomerular
ltration rate was estimated using the 4-variable Modifica-
ion of Diet in Renal Disease equation (19). All biochemical
esting was performed by personnel blinded to clinical
utcomes and treatment allocation.
tatistical analysis. We used analysis of variance and
hi-square tests to test for differences in continuous and
ategoric baseline characteristics between quartiles of BNP
nd NT-proBNP. The overall F-test is reported for the
nalysis of variance models.
In separate models, we used Cox proportional hazards
odels to examine the association between BNP and
T-proBNP and the following prospectively defined out-
ome variables: cardiovascular mortality, fatal or nonfatal
yocardial infarction, fatal or nonfatal stroke, and fatal or
onfatal new congestive heart failure requiring hospitaliza-
ion. All events were confirmed by review of medical
ecords, with blinded review by an end points committee for
ardiovascular death, fatal and nonfatal myocardial infarc-
ion, and fatal and nonfatal stroke.
Patients were censored at their last visit. A test of the
nteraction between BNP and treatment and between NT-
roBNP and treatment assignment was included. Subse-
uent models were adjusted for treatment assignment and
aseline variables known to be important predictors of
ardiovascular events: age, gender, body mass index, ejection
raction 50%, estimated glomerular filtration rate, current
moking, history of hypertension or measured hypertension,
istory of myocardial infarction, history of diabetes, history
f stroke, history of percutaneous coronary intervention,
istory of coronary artery bypass grafting, total cholesterol,
-reactive protein, use of a beta-blocker, use of a lipid-
owering drug, use of aspirin or an antiplatelet medication,
nd use of a diuretic. To examine the potential influence of
nterim heart failure events on cardiovascular death, addi-
ional models were adjusted for interim heart failure as a
ime-dependent variable and censored patients at the time
f their heart failure event. Both BNP and NT-proBNP
ere examined as continuous variables (per 1 standard
eviation of the logarithmic transformation). To determine
f there was a gradient effect, BNP and NT-proBNP were
lso examined using gender-specific quartiles. Kaplan- ceier curves were generated to show the cumulative inci-
ence for each of the end points. Residual analysis was used
o assess model fit. The collinearity index was used to check
or linear combinations among covariates (20). To assess the
iscriminative ability of BNP and NT-proBNP, we com-
uted the c-index for each outcome and compared them
etween BNP and NT-proBNP (21,22).
Pearson correlation was used to describe the association
etween log BNP, log NT-proBNP, and risk factors. The
AS analysis system version 9.1 was used for all analyses
SAS Institute, Cary, North Carolina).
esults
haracteristics at baseline. Characteristics at baseline in
atients included in this biomarker substudy (n  3,761)
id not differ markedly from those of patients not included
n this analysis (n  4,529; data not shown).
Characteristics of the patients according to their BNP
nd NT-proBNP concentrations at baseline are shown in
ables 1 and 2, respectively. The median value of BNP was
2.6 pg/ml (interquartile range 24.9 to 101.4 pg/ml; normal
alue 100 pg/ml), and the median value of NT-proBNP
as 139.3 pg/ml (interquartile range 71.3 to 272.1 pg/ml;
ormal value: age 75 years: 125 pg/ml; age 75 years:
450 pg/ml). B-type natriuretic peptide and NT-proBNP
orrelated significantly (r  0.62; p  0.001). Modest
orrelations were observed between natriuretic peptides and
jection fraction (BNP: r  0.09; p  0.001; NT-
roBNP: r  0.18; p  0.001), estimated glomerular
ltration rate (BNP: r  0.14; p  0.001; NT-proBNP:
 0.22; p  0.001), body mass index (BNP: r  0.09;
 0.001; NT-proBNP: r  0.12; p  0.001), and
ystolic blood pressure (BNP: r  0.11; p  0.001;
T-proBNP: r  0.15; p  0.001). Both BNP (r  0.27;
 0.001) and NT-proBNP (r  0.39; p  0.001)
orrelated more closely with patient age.
elation to fatal and nonfatal cardiovascular events. Dur-
ng a median of 4.8 years of follow-up there were 127
ardiovascular deaths, 104 fatal or first nonfatal congestive
eart failure events, 241 fatal or first nonfatal acute myo-
ardial infarction events and 86 fatal or first nonfatal stroke
vents. By univariable analyses, both BNP and NT-proBNP
ere significant predictors of cardiovascular mortality, fatal
r nonfatal stroke, and fatal or nonfatal congestive heart
ailure but not fatal or nonfatal acute myocardial infarction
Table 3).
By multivariable analyses, after adjustment for risk fac-
ors, NT-proBNP remained a significant independent pre-
ictor of cardiovascular mortality (Fig. 1), fatal or nonfatal
ongestive heart failure (Fig. 2), and fatal or nonfatal stroke
Fig. 3, Table 4). Consistent results were obtained regard-
ess of whether the peptides were treated as logarithmically
ransformed continuous variable (Table 4) or as categoric
ariables (Table 5). Adjustment or censoring for interim
ongestive heart failure had only minor impact on the
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BNP, NT-proBNP, and Prognosis in Stable CAD July 17, 2007:205–14ssociation between NT-proBNP and risk of cardiovascular
eath. For example, adjustment for interim congestive heart
ailure reduced the hazard ratio for the fourth versus first
uartile of NT-proBNP marginally from 4.9 (95% confi-
ence interval 2.2 to 10.7) to 4.5 (95% confidence interval
.0 to 9.8).
Calculation of the c-index as a measure of overall prog-
ostic accuracy demonstrated that in univariable analysis
T-proBNP performed significantly better than BNP as a
redictor of cardiovascular mortality, fatal or nonfatal
troke, and fatal or nonfatal congestive heart failure; neither
redicted fatal or nonfatal myocardial infarction (Table 6).
or the end point of fatal and nonfatal congestive heart
ailure, addition of either BNP or NT-proBNP to the
ultivariable model resulted in statistically significant im-
roved prognostic accuracy, as evaluated by the c-index,
ompared with the conventional risk factor model. For
ardiovascular mortality, NT-proBNP, but not BNP, re-
ulted in statistically significant improved prognostic accu-
haracteristics of Patients According to BNP Concentrations at Ba
Table 1 Characteristics of Patients According to BNP Concent
Baseline Characteristics
1st Quartile
(n  936);
Men  15–24 pg/ml;
Women  15–32 pg/ml
2nd
(n 
Men  2
Women 
Age, mean  SD, yrs 60.7  7.4 62.9
Female gender, n (% of patients) 176 (18.8) 17
Caucasian race, n (% of patients) 878 (93.8) 86
Body mass index, mean  SD, kg/m2 29.0  4.9 28.7
Medical history, n (% of patients)
Documented myocardial infarction 512 (54.7) 50
Angina pectoris 689 (73.6) 69
PCI 487 (52.0) 43
CABG 214 (22.9) 31
Diabetes 134 (14.3) 16
Hypertension 379 (40.5) 40
Stroke 24 (2.6) 3
Current smoker 171 (18.3) 15
Mean blood pressure, mean  SD, mm Hg
Systolic 132  15.5 132
Diastolic 79.1  9.7 78.1
Laboratory determinations, mean  SD
eGFR, ml/min 81.1  21.6 79.3
Serum cholesterol, mg/dl 196  39.9 191
C-reactive protein 3.69  8.17 3.04
LV ejection fraction 40% and 50%,
n (% of patients)
106 (11.3) 10
Medications, n (% of patients)
Allocation to trandolapril 465 (49.7) 47
Calcium-channel blocker 328 (35.0) 31
Beta-blocker 481 (51.4) 59
Aspirin/antiplatelet medication 854 (91.2) 87
Lipid-lowering drug 722 (77.1) 69
Nonpotassium-sparing diuretic 76 (8.1) 7
Digitalis 13 (1.4) 2
Based on F-tests for continuous data and chi-square statistics for categoric data.
BNP  B-type natriuretic peptide; CABG  coronary artery bypass grafting; eGFR  estimatedacy (Table 7). cIn the main PEACE trial the incidence of the primary
nd point—death from cardiovascular causes, myocardial
nfarction, or coronary revascularization—was not signifi-
antly different between the ACE inhibitor or placebo
roup. However, significantly fewer patients in the ACE
nhibitor group than in the placebo group were hospitalized
ith or died of congestive heart failure. No interaction was
bserved between BNP or NT-proBNP and randomized
reatment group. That is, the association between treatment
roup (ACE inhibition or placebo) and each outcome did
ot vary according to BNP or NT-proBNP concentration
data not shown).
iscussion
he salient findings of this large-scale study of low-risk
atients with stable coronary artery disease and preserved
eft ventricular function are: 1) both BNP and NT-proBNP
re predictive of the incidence of cardiovascular death,
e
s at Baseline
ile
);
pg/ml;
1 pg/ml
3rd Quartile
(n  939);
Men  51–98 pg/ml;
Women  61–115 pg/ml
4th Quartile
(n  938);
Men  98–2,660 pg/ml;
Women  115–2,427 pg/ml p Value*
64.5  8.1 66.6  8.2 0.001
) 178 (19.0) 177 (18.9) 1.00
) 855 (91.1) 844 (90.0) 0.02
28.4  4.7 27.9  4.5 0.001
) 545 (58.0) 547 (58.4) 0.09
) 681 (72.5) 684 (73.0) 0.95
) 432 (46.1) 357 (38.1) 0.001
) 372 (39.6) 437 (46.6) 0.001
) 161 (17.1) 159 (17.0) 0.27
) 423 (45.0) 467 (49.8) 0.001
42 (4.5) 55 (5.9) 0.004
) 117 (12.5) 125 (13.3) 0.01
.1 133  17.0 137  18.1 0.001
77.6  9.3 77.3  10.3 0.001
.7 76.6  17.5 74.7  18.8 0.001
.8 191  38.2 190  39.5 0.002
1 3.61  11.6 3.54  5.89 0.28
) 148 (15.8) 178 (19.0) 0.001
) 483 (51.4) 452 (48.2) 0.57
) 306 (32.6) 297 (31.7) 0.44
) 586 (62.4) 670 (71.6) 0.001
) 861 (91.7) 832 (88.9) 0.02
) 651 (69.3) 629 (67.2) 0.001
86 (9.2) 109 (11.6) 0.01
30 (3.2) 55 (5.9) 0.001
lar filtration rate; LV  left ventricular; PCI  percutaneous coronary intervention.selin
ration
Quart
941
4–51
32–6
 7.7
9 (19.0
5 (91.9
 4.8
4 (53.6
1 (73.4
9 (46.7
5 (33.5
1 (17.1
6 (43.1
6 (3.8)
2 (16.2
 16
 9.9
 18
 37
 5.2
8 (11.5
1 (50.2
9 (33.9
3 (63.0
5 (93.0
9 (74.4
1 (7.5)
5 (2.7)ongestive heart failure, and stroke, but neither peptide
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July 17, 2007:205–14 BNP, NT-proBNP, and Prognosis in Stable CADredicts the incidence of myocardial infarction; 2) after
djustment for conventional risk factors, both BNP and
T-proBNP remained significant predictors of congestive
eart failure, but only NT-proBNP remained a predictor of
ardiovascular death and stroke; 3) adjustment for the
ncidence of heart failure did not diminish the merit of
T-proBNP as a predictor of cardiovascular mortality,
uggesting that mechanisms other than prediction of con-
estive heart failure are responsible for this relationship; 4)
haracteristics of Patients According to NT-ProBNP Concentration
Table 2 Characteristics of Patients According to NT-ProBNP Co
Baseline Characteristics
1st Quartile
(n  943);
Men  5–66 pg/ml;
Women  5–105 pg/ml
2nd
(n 
Men  66
Women  1
Age, mean  SD, yrs 59.9  7.1 62.8
Female gender, n (% of patients) 178 (18.9) 178
Caucasian race, n (% of patients) 847 (89.8) 863
Body mass index, mean  SD, kg/m2 29.1  4.9 28.8
Medical history, n (% of patients)
Documented myocardial infarction 462 (49.0) 507
Angina pectoris 693 (73.5) 692
PCI 523 (55.5) 443
CABG 178 (18.9) 307
Diabetes 161 (17.1) 151
Hypertension 390 (41.4) 402
Stroke 24 (2.5) 29
Current smoker 155 (16.5) 156
Mean blood pressure, mean  SD, mm Hg
Systolic 131  15.0 132
Diastolic 79.1  9.8 78.1
Laboratory determinations, mean  SD
eGFR, ml/min 82.2  18.7 79.5
Serum cholesterol, mg/dl 196  38.6 194
C-reactive protein 3.10  5.44 3.11
LV ejection fraction 40% and 50%,
n (% of patients)
76 (8.1) 107
Medications, n (% of patients)
Allocation to trandolapril 492 (52.2) 454
Calcium-channel blocker 352 (37.3) 333
Beta-blocker 452 (47.9) 558
Aspirin/antiplatelet medication 873 (92.6) 868
Lipid-lowering drug 697 (74.0) 690
Nonpotassium-sparing diuretic 62 (6.6) 67
Digitalis 13 (1.4) 22
Based on F-tests for continuous data and chi-square statistics for categoric data.
NT-proBNP  N-terminal pro-B-type natriuretic peptide; other abbreviations as in Table 1.
Association Between BNPs as Continuous Variaand Cardi vascular Outcomes Adjusted for Rand
Table 3 Association Between BNPs as Contand Cardiovascular Outcomes Adjus
Outcome
BNP
HR (95% CI)*
Cardiovascular mortality 1.28 (1.08–1.51)
Fatal/nonfatal MI 0.95 (0.83–1.08)
Fatal/nonfatal CHF 1.92 (1.61–2.27)
Fatal/nonfatal stroke 1.35 (1.10–1.65)*Per 1 SD pg/ml in log BNP and log NT-proBNP.
CHF  congestive heart failure; CI  confidence interval; HR  hazard ratio; Mddition of a single NT-proBNP measurement provides
mproved overall prognostic accuracy for the end points of
ardiovascular mortality and heart failure compared with
hat obtained from a model consisting of conventional risk
actors, whereas BNP provided improved prognostic accu-
acy for the end point of heart failure; and 5) natriuretic
eptide determination did not identify a subset of patients
ho experienced a greater degree of benefit with ACE
nhibition. These observations may have important impli-
aseline
trations at Baseline
le
);
pg/ml;
96 pg/ml
3rd Quartile
(n  939);
Men  127–253 pg/ml;
Women  196–372pg/ml
4th Quartile
(n  941);
Men  253–5,590 pg/ml;
Women  372–4,593 pg/ml p Value*
64.1  7.9 67.8  8.0 0.001
) 178 (19.0) 179 (19.0) 1.00
) 867 (92.3) 871 (92.6) 0.12
28.5  4.7 27.6  4.5 0.001
) 559 (59.6) 584 (62.1) 0.001
) 694 (74.0) 673 (71.5) 0.60
) 400 (42.6) 352 (37.4) 0.001
) 408 (43.5) 447 (47.5) 0.001
) 143 (15.2) 161 (17.1) 0.65
) 416 (44.3) 474 (50.4) 0.001
42 (4.5) 64 (6.8) 0.001
) 133 (14.2) 122 (13.0) 0.23
.4 133  16.5 137  18.5 0.001
77.7  9.8 77.1  10.1 0.001
.6 77.7  18.7 72.1  18.0 0.001
.2 189  37.4 190  40.0 0.001
6 3.59  7.42 4.08  11.12 0.02
) 136 (14.5) 223 (23.7) 0.001
) 456 (48.6) 473 (50.3) 0.32
) 290 (30.9) 278 (29.5) 0.001
) 663 (70.7) 662 (70.4) 0.001
) 862 (91.9) 825 (87.7) 0.001
) 693 (73.9) 624 (66.3) 0.001
86 (9.2) 130 (13.8) 0.001
26 (2.8) 62 (6.6) 0.001
ation Status
s Variables
or Randomization Status
NT-ProBNP
p Value HR (95% CI)* p Value
0.004 2.00 (1.69–2.36) 0.001
0.43 1.05 (0.93–1.18) 0.43
0.001 2.81 (2.33–3.38) 0.001
0.003 1.93 (1.58–2.36) 0.001s at B
ncen
Quarti
938
–127
05–1
 7.6
(19.0
(92.0
 4.7
(54.1
(73.8
(47.2
(32.7
(16.1
(42.9
(3.1)
(16.6
 16
 9.3
 20
 39
 7.0
(11.4
(48.4
(35.5
(59.6
(92.6
(73.6
(7.2)
(2.3)blesomiz
inuou
ted fI myocardial infarction; other abbreviations as in Tables 1 and 2.
c
p
B
e
(
s
y
v
N
t
c
o
o
d
t
b
d
l
b
m
c
t
a
a
f
p
b
i
t
m
d
t
B
d
p
w
c
f
p
p
a
d
t
a
l
t
p
T
a
p
a
210 Omland et al. JACC Vol. 50, No. 3, 2007
BNP, NT-proBNP, and Prognosis in Stable CAD July 17, 2007:205–14ations for the clinical use of BNPs in the large group of
atients with stable coronary artery disease.
NPs and specific cardiovascular events. In contrast to
arlier studies in patients with stable coronary artery disease
9–13), the present study provides data on a range of
pecific cardiovascular end points, which also permits anal-
sis of the association between these end points and cardio-
ascular death. The observation that neither BNP nor
T-proBNP predicted fatal and nonfatal myocardial infarc-
ion suggests that the association between NT-proBNP and
ardiovascular death is unlikely to be explained by prediction
f myocardial infarction. These results are in line with those
f 3 large acute coronary syndrome studies that failed to
emonstrate an independent association between BNPs and
he incidence of coronary events (4,6,8), Not unexpectedly,
Figure 1 NT-ProBNP and Cardiovascular Death
Kaplan-Meier curves showing the cumulative incidence of death due to a car-
diovascular cause in patients according to quartiles of plasma N-terminal pro-B-
type natriuretic peptide (NT-proBNP) concentrations.
Figure 2 NT-ProBNP and Heart Failure
Kaplan-Meier curves showing the cumulative incidence of fatal or nonfatal con-
gestive heart failure (CHF) in patients according to quartiles of plasma N-termi-
nal pro-B-type natriuretic peptide (NT-proBNP) concentrations.both BNP and NT-proBNP were powerful and indepen-
ent predictors of heart failure. However, in the present
ow-risk population, prediction of heart failure appeared to
e of modest importance for prediction of cardiovascular
ortality, because BNP failed to independently predict
ardiovascular mortality despite a strong association with
he incidence of heart failure. Interestingly, a similar lack of
ssociation between BNP and cardiovascular mortality, after
djustment for echocardiographic indices of ventricular
unction, was observed in the Framingham Heart Study
opulation that also excluded subjects with heart failure at
aseline (23). Moreover, adjustment for or censoring of
ncident heart failure in the present study did not impact on
he merit of NT-proBNP as a predictor of cardiovascular
ortality. The association between NT-proBNP and car-
iovascular mortality may therefore be ascribed to predic-
ion of neither heart failure nor myocardial infarction.
NP and NT-proBNP as prognostic indicators. Existing
ata on the relative prognostic value of BNP and NT-
roBNP are still scarce. One recent publication of patients
ith coronary artery disease suggested that the two are
omparable as predictors of all-cause mortality and heart
ailure hospitalizations, but the study included a large
roportion of patients with chronic heart failure and im-
aired systolic function and the results may not be gener-
lizable to low-risk patients with stable coronary artery
isease (13). Moreover, that study restricted their analysis to
he end points of all-cause mortality or all-cause mortality
nd heart failure. The study also included a substantially
ower number of study subjects than the present investiga-
ion and may as a consequence have had less statistical
ower to detect differences between BNP and NT-proBNP.
he use of in-house biochemical assays for analysis of BNP
nd NT-proBNP also make direct comparisons with the
resent data and other studies using commercially available
ssays somewhat difficult. Moreover, the duration of time
Figure 3 NT-ProBNP and Stroke
Kaplan-Meier curves showing the cumulative incidence of fatal or nonfatal
stroke in patients according to quartiles of plasma N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) concentrations.etween blood sampling and determination of circulating
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July 17, 2007:205–14 BNP, NT-proBNP, and Prognosis in Stable CADeptide concentrations was substantially longer for NT-
roBNP than for BNP, which may have introduced bias in
avor of BNP in that study.
The relative prognostic value of BNP and NT-proBNP
as also been evaluated in 2 other recent studies. The
ssociation between BNP and NT-proBNP and all-cause
ortality was assessed in a community-based cohort of
ubjects free of heart failure at baseline (24). In a model
ontaining both peptides, only NT-proBNP was predictive
f outcome. However, because no overall index of prognos-
ic value was provided, the clinical significance of the
tatistical difference is somewhat difficult to assess. More-
ver, end points other than mortality were not examined.
he relative value of BNP and NT-proBNP has also been
xamined in a large population of patients with symptom-
tic chronic heart failure (25). The predictive ability of BNP
nd NT-proBNP did not differ concerning the end point of
ll-cause mortality, but NT-proBNP provided superior
rognostic information concerning the combined mortality
nd morbidity end point and concerning heart failure
ospitalizations.
The reasons for the observed differences in prognostic
alue between BNP and NT-proBNP remain somewhat
nclear. Early reports suggested that NT-proBNP is a more
ensitive marker of asymptomatic left ventricular dysfunc-
ion than BNP (26,27), and this observation has been
onfirmed by a recent population-based study (28). A closer
elation to renal function may not be fully accounted for by
djustment for estimated glomerular filtration rate and
lood pressure and may represent a potential link to adverse
utcome. A third possibility is that a longer half-life of
T-proBNP makes this peptide less prone to intraday
ariability than BNP, making a single measurement of
T-proBNP a more accurate and robust index of cardio-
ascular function and prognosis than a single measurement
f BNP.
Finally, we cannot rule out the possibility that differences
n in vitro stability and analytical precision between BNP
nd NT-proBNP assays may have contributed to the
bserved differences in prognostic merit. In a substudy of
he SAVE (Survival and Ventricular Enlargement) trial,
Multivariable* Analysis of the Association BetwBNPs s Continuous Variables and C rdiovascul
Table 4 Multivariable* Analysis of the AssoBNPs as Continuous Variables and
Outcome
BNP
HR (95% CI)†
Cardiovascular mortality 1.06 (0.87–1.28)
Fatal/nonfatal MI 0.91 (0.77–1.07)
Fatal/nonfatal CHF 1.62 (1.32–1.97)
Fatal/nonfatal stroke 1.15 (0.91–1.45)
*Adjusted for treatment assignment, age, gender, body mass index, e
history of hypertension or measured hypertension, history of myocard
coronary intervention, history of coronary artery bypass grafting, total
drug, use of aspirin or an antiplatelet medication, and use of a diuret
Abbreviations as in Tables 1 to 3.T-pro-A-type natriuretic peptide (ANP) was found to be astronger prognostic indicator than ANP (29), and this
ifference in prognostic value may have been based on the
arked in vitro stability difference between ANP and
T-proANP. Data concerning the in vitro stability of BNP
ave been somewhat conflicting. Early studies suggested
hat BNP is stable in whole blood and EDTA plasma for at
east 24 h (30,31). More recent data suggest that this may
epend on the assay used. According to the manufacturer of
he BNP assay used in the present study, BNP is stable for
h in whole blood and in EDTA plasma, and the recovery
f BNP may potentially be diminished if collected in glass
ubes. Moreover, long-term storage of frozen samples may
lso be associated with degradation of BNP. For instance, in
ne recent study using the Abbott AxSym assay, BNP
mmunoreactivity in EDTA plasma samples stored at
20°C for 2 to 4 months were reported to be 50%
ompared with levels measured within 4 h of blood collec-
ion (32). On the other hand, no association between the
uration of storage and natriuretic peptide concentrations
ere observed in the present study. The observation of a
trong and independent relationship to incident heart failure
lso argues strongly against significant degradation of BNP
n the present study. However, the differences in prognostic
erit between BNP and NT-proBNP for other end points
ay potentially be attributed to differences in in vitro
tability, and these findings may not be relevant for samples
easured immediately after blood collection in clinical
ay-to-day testing.
Differences in analytic performance of the assays may also
ave affected the results. In accordance with a study com-
aring the assays used in the present analysis (33), the
ow-range sensitivity and analytic precision of the NT-
roBNP assay appeared to be superior to those of the BNP
ssay. Combined, these factors may have contributed to a
ower signal-to-noise ratio for BNP than for NT-proBNP,
ranslating into reduced prognostic power for BNP for
on-heart failure end points.
hat BNP and NT-proBNP concentrations define in-
reased risk? Identification of threshold concentrations of
NP and NT-proBNP that define increased risk in clini-
ally stable patients would be helpful for the clinician. The
tcomes
n Between
ovascular Outcomes
NT-ProBNP
p Value HR (95% CI)† p Value
0.57 1.69 (1.38–2.07) 0.001
0.24 1.02 (0.87–1.19) 0.84
0.001 2.35 (1.86–2.98) 0.001
0.24 1.63 (1.26–2.12) 0.001
fraction 50%, estimated glomerular filtration rate, current smoking,
rction, history of diabetes, history of stroke, history of percutaneous
erol, C-reactive protein, use of a beta-blocker, use of a lipid-lowering
1 SD pg/ml in log BNP and NT-proBNP.eenar Ou
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BNP, NT-proBNP, and Prognosis in Stable CAD July 17, 2007:205–14rials of acutely dyspneic patients and does not take into
ccount the confounding effects of age and gender. Because
t is not based on healthy individuals it should not
e regarded as a conventional upper normal value and may
e imperfect for defining risk in stable coronary artery
isease patients. In fact, this was a main argument for not
sing those cut-offs in the present analyses. Instead, we
nalyzed BNP and NT-proBNP as continuous variables and
y quartile. Although there is some degree of peptide-
pecific and end point–specific variations, the current data
uggest that the risk associated with increasing BNP and
T-proBNP concentrations is largely monotonic and does
ot allow definition of a specific threshold value.
ncremental prognostic value of BNPs. Multiple biomar-
ers have been proposed as prognostic tools in patients with
oronary artery disease, but few have been demonstrated to
rovide clinically relevant incremental prognostic value to
onventional risk factors (14). A recent publication from the
OPE (Heart Outcomes Prevention Evaluation) study in
atients with cardiovascular risk factors suggests that NT-
roBNP provides incremental prognostic information con-
erning the combined end point of cardiovascular death,
troke, and myocardial infarction above that obtained by
odels of traditional risk factors (34). The present study
xtends these findings by showing that, in patients with
stablished coronary artery disease, adding BNP and NT-
roBNP to the best available model results in statistically
ignificant improvement in predictive ability for the indi-
idual end point of heart failure, as evaluated by the c-index.
oreover, NT-proBNP improved the predictive ability of
he model for the end point of cardiovascular death. In
verall Prognostic Merit of BNP and NT-ProBNP
Table 6 Overall Prognostic Merit of BNP and NT-ProBNP
Outcome BNP* NT-ProBNP* p Value†
Cardiovascular mortality 0.58 (0.53–0.63) 0.68 (0.63–0.73) 0.001
Fatal and nonfatal MI 0.53 (0.49–0.57) 0.53 (0.49–0.56) 0.84
Fatal and nonfatal CHF 0.69 (0.64–0.73) 0.74 (0.69–0.79) 0.005
Fatal and nonfatal stroke 0.61 (0.55–0.67) 0.70 (0.65–0.75) 0.001
C-statistic (95% CI). †Between NT-proBNP and BNP as estimated by the nonparametric approach
f DeLong et al. (22).
Abbreviations as in Tables 1 to 3.
ncremental Prognostic Value ofNP and NT- BNP o the Best Availableultivariab e* Model for Cardi vascu r End Points
Table 7
Incremental Prognostic Value of
BNP and NT-ProBNP to the Best Available
Multivariable* Model for Cardiovascular End Points
Outcome Covariates†
Covariates
and BNP†
Covariates
and NT-ProBNP†
CV mortality 0.74 (0.70–0.79) 0.75 (0.71–0.80) 0.77 (0.73–0.81)‡
CHF 0.82 (0.78–0.86) 0.84 (0.80–0.87)‡ 0.85 (0.81–0.88)‡
Stroke 0.78 (0.73–0.83) 0.78 (0.73–0.83) 0.80 (0.76–0.85)
Covariates include treatment assignment, age, gender, body mass index, ejection fraction50%,
stimated glomerular filtration rate, current smoking, history of hypertension or measured hyper-
ension, history of myocardial infarction, history of diabetes, history of stroke, history of percuta-
eous coronary intervention, history of coronary artery bypass grafting, total cholesterol, C-reactive
rotein, use of a beta-blocker, use of a lipid-lowering drug, use of aspirin or an antiplatelet
edication, and use of a diuretic. †C-statistic (95% CI). ‡p  0.05 as estimated by theT C F F F
*A
d
of
p A nonparametric approach of DeLong et al. (22).
CV  cardiovascular; other abbreviations as in Tables 1 to 3.
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July 17, 2007:205–14 BNP, NT-proBNP, and Prognosis in Stable CADontrast to the HOPE substudy, the best available model in
he present study included an objective measure of ventric-
lar function.
rediction of the effect of ACE inhibition. In contrast to
he HOPE (16) and EUROPA (EURopean trial On
eduction of cardiac events with Perindopril in stable
oronary Artery disease) (15) studies, in the PEACE trial,
CE inhibition did not result in any reduction in the
rimary outcome (i.e., cardiovascular mortality, myocardial
nfarction, or coronary revascularization) (17). One possible
xplanation for the discrepant result is the considerably
ower risk of the patients included in the PEACE trial than
n the HOPE and the EUROPA trials. Because BNP and
T-proBNP strongly relate to mortality in a wide spectrum
f cardiovascular disease, including patients with stable
oronary artery disease (9–13), it seemed reasonable to
ypothesize that measurement of BNP and NT-proBNP
ight identify patients who benefit from ACE inhibition.
he failure of BNP and NT-proBNP to be helpful in this
espect may be related to the inability of BNPs to predict
oronary ischemic events, which constituted the majority of
vents in the PEACE trial. It is also conceivable that the
eutral overall results of the PEACE trial may have reduced
he likelihood of detecting a significant interaction between
atriuretic peptide levels and benefit of ACE inhibition.
tudy limitations. Limitations of the present study include
he selection of patients participating in clinical trials who
ay not be representative of all stable coronary artery
isease patients, as well as the use of biobank specimens
btained at multiple sites and shipped for peptide analysis.
tudy strengths. Strengths of the study include the pro-
pective design of the PEACE biomarker substudy, the
arge and well characterized patient sample, the long dura-
ion of follow-up, accuracy of recording of cardiovascular
nd points, and adjustment for important cardiovascular risk
actors.
linical implications. In low-risk patients with stable
oronary artery disease and preserved left ventricular func-
ion, BNPs provide strong and incremental prognostic
nformation to traditional risk factors. The clinical implica-
ions of elevated BNPs are less clear. Lack of prediction of
yocardial infarction suggests that determination of BNPs
ay not be useful for selection of anti-ischemic therapies in
ow-risk patients. Contrary to our expectations, BNP and
T-proBNP failed to identify stable coronary artery disease
atients who benefit from ACE inhibition. In conclusion,
urrent data support measurement of BNPs in low-risk
opulations for prognostic assessment but do not provide a
andate for the use of these peptides for tailoring therapy in
ndividual patients.
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